Empowering Precision Cancer Research

Our oncology portfolio is built to support drug developers, academic researchers, and clinicians in advancing cancer therapeutics. We provide high-precision, immunology-driven analytics to assess efficacy, safety, and immunogenicity of cancer vaccines, monoclonal antibodies, and targeted treatments.

Monoclonal Antibody (mAb) Evaluation

Cytotoxicity Assays
Quantify complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis (via caspase activation, TUNEL, flow cytometry).
Immune Profiling
Characterize T cells, B cells, and NK cells with multiparametric flow cytometry. Cytokine release assays to detect potential cytokine storm risks.
Toxicity Studies
In vitro and in vivo assessments including hematology, organ histology, and off-target binding using tissue microarrays.
Pharmacokinetics/Pharmacodynamics (PK/PD)
Quantification of circulating mAbs, receptor occupancy studies via ELISA or MSD.
Immunogenicity
Anti-drug antibody (ADA) detection to assess neutralizing antibody formation.

Cancer Vaccine Evaluation

T Cell Responses
ELISpot and ICS for IFN-γ, IL-2, TNF-α quantification.
Immune Activation Markers
Flow cytometry for CD69, CD40L, and related activation markers.
Tumor Challenge Studies
In vivo efficacy using orthotopic/xenograft models. Testing of vaccine combinations with checkpoint inhibitors.
Neoantigen Analysis
Mass spectrometry and immunopeptidomics to detect patient-specific T cell responses.
Antibody Titers
IgG, IgA, and IgM quantification for vaccine-induced humoral responses.

Specialized Oncology Services

Immune Repertoire & Single-Cell Sequencing
TCR/BCR sequencing and tumor microenvironment analysis via single-cell RNA-seq.
Biomarker Discovery
Proteomic, transcriptomic, and cytometric biomarker identification and validation.
Companion Diagnostics
Assay development to correlate treatment responses with clinical outcomes.
Immunotherapy Combinations
Synergy testing with CAR-T, checkpoint inhibitors, and small molecules.
Patient-Derived Xenografts (PDX)
Expansion into PDX for personalized therapeutic assessments in vivo.